Cargando…

HDAC inhibition potentiates immunotherapy in triple negative breast cancer

Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various types of cancer, including breast cancer. Her...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terranova-Barberio, Manuela, Thomas, Scott, Ali, Niwa, Pawlowska, Nela, Park, Jeenah, Krings, Gregor, Rosenblum, Michael D., Budillon, Alfredo, Munster, Pamela N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768393/ https://www.ncbi.nlm.nih.gov/pubmed/29371976 http://dx.doi.org/10.18632/oncotarget.23169

Ejemplares similares

Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer
por: Park, Jeenah, et al.
Publicado: (2018)

Host histone acetylation unlocks HDAC inhibitor potential
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2020)

Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
por: Raha, Paromita, et al.
Publicado: (2015)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
por: Li, Mengxing, et al.
Publicado: (2021)

Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis
por: Menbari, Mohammad-Nazir, et al.
Publicado: (2020)

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
por: Camarda, Roman, et al.
Publicado: (2016)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
por: Roca, Maria Serena, et al.
Publicado: (2019)

HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer
por: Zhu, Mengdi, et al.
Publicado: (2022)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models
por: Thomas, Scott, et al.
Publicado: (2023)

HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation
por: Alothaim, Tahiyat, et al.
Publicado: (2021)

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
por: Cocco, Stefania, et al.
Publicado: (2022)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
por: Llinàs-Arias, Pere, et al.
Publicado: (2021)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2023)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer
por: Nunziata, Carmine, et al.
Publicado: (2019)

Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells
por: Sulaiman, Andrew, et al.
Publicado: (2018)

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
por: Ashraf, Yahya, et al.
Publicado: (2019)

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h4svg0174r63ctuqnc29esupt4